Processing method for reducing toxicity of rhizoma arisaematis
Through a new manufacturing method, including soaking, drying and puffing steps, the problems of complex and long cycles of traditional Alan Star manufacturing methods are solved, and the effects of shortening production cycles, reducing costs and improving product quality are achieved.
Patent Information
- Application Number
- CN202510199513.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-02-24
- Publication Date
- 2025-05-13
AI Technical Summary
The traditional Alan Star production method has problems such as long production cycle, complex process, a wide variety of auxiliary materials, and may lead to excessive intake of aluminum ions, and the quality of the preparation is difficult to standardize.
A new preparation method is adopted, including soaking the Aranacin medicinal materials in clean water until they are heart-permeable, then cutting into blocks, blow drying and puffing of single-screw grain expander, and finally cooling and vacuum packaging.
This method can significantly shorten the production cycle of Tiannanxing's preparation products and reduce production costs, without using any auxiliary materials. The quality of the preparation products is stable and controllable, and the content of active ingredients and efficacy are better than that of the traditional pharmacopoeia method.
Smart Images
Figure CN119970889A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of Chinese medicine processing, in particular to a processing method for reducing the toxicity of rhizoma arisaeodorae. Background Art
[0002] Arisaema is the dried tuber of Arisaema, Arisaema heterophyllum or Arisaema mandshurica, which belong to the Araceae family. Chinese medicine believes that Arisaema is bitter, pungent, warm and poisonous. It enters the lung, liver and spleen meridians, and has the effects of drying dampness and resolving phlegm, dispersing nodules and reducing swelling, and dispelling wind and stopping spasms. It is used externally to treat carbuncle, snake and insect bites. However, the raw decoction pieces of Arisaema are highly toxic and irritating, which manifests as a strong sense of numbness in the tongue and sore throat. When the raw powder is taken up to 2g, throat edema and loss of voice will occur, causing harm to the patient. Therefore, it is necessary to be cautious when taking Arisaema that has not been processed. In order to make it safe and effective, the Chinese medicine industry often uses Chinese medicine processing technology to reduce its toxicity.
[0003] The traditional processing method of Arisaema is mostly the replication method, which refers to adding one or several auxiliary materials to the selected Chinese medicinal materials, and repeatedly processing them to a specified degree according to the prescribed procedures, or soaking, soaking, bleaching, or steaming or multiple methods. It is mainly suitable for highly toxic drugs, the toxicity of which can be reduced or eliminated after replication, such as Pinellia, Arisaema, and Rhizoma Aconiti Lateralis. This method often uses a variety of auxiliary materials. The selection of different auxiliary materials for processing drugs can have different effects on the performance of the drugs. Studies have shown that the toxic and irritating components in Arisaema are calcium oxalate needle crystal bundles and lectin toxic proteins. After processing according to the processing method specified in the Pharmacopoeia of the People's Republic of China, the toxic needle crystals and toxic proteins originally contained in Arisaema are destroyed. Because after processing with multiple auxiliary materials, the calcium oxalate needle crystals are dissolved, and the lectin toxic proteins connected to the toxic needle crystals are denatured and lose their activity. The content of both is greatly reduced compared with the raw product. However, the replication method has the disadvantages of long processing cycle, complex processing technology, and a wide variety of processing auxiliary materials. Moreover, alum is often used as an auxiliary material for detoxification during the preparation of alum. If patients take alum-processed arisaema for a long time, excessive intake of aluminum ions will cause damage to brain neurons. In addition, the arisaema prepared by the traditional replication method has the disadvantage that the quality evaluation of arisaema is difficult to standardize. Summary of the invention
[0004] In order to solve the above problems, that is, to solve the problems raised by the above background technology, the present invention proposes a processing method for reducing the toxicity of Arisaema cinerea, and the specific technical scheme is as follows:
[0005] A processing method for reducing the toxicity of Arisaema cinerea, characterized in that the method comprises the following steps: taking Arisaema cinerea with a diameter of about 3-8 cm, adding clean water to cover it and soaking it, changing the water once in the morning, noon and evening every day, soaking it continuously for 36-48 hours until it is thoroughly soaked, taking it out, draining the water, cutting it into cubic blocks with a side length of 1.0-2.0 cm, drying it with forced air at 30-60°C for 6-10 hours, taking it out, placing it in a single-screw grain extruder for extrusion, collecting the finished products extruded from the discharge port, bagging them after cooling, and vacuum packaging them.
[0006] Preferably, the method comprises the following steps: taking a herb of Arisaema with a diameter of about 6 cm, adding clean water to cover it and soaking it, changing the water once in the morning, noon and evening every day for 48 hours until it is thoroughly soaked, taking it out, draining the water, cutting it into cubic blocks with a side length of 1-1.5 cm, drying it with air at 40°C for 8 hours, taking it out, placing it in a single-screw cereal extruder for extrusion, collecting the finished product extruded from the discharge port, bagging it after cooling it, and vacuum packaging it.
[0007] Preferably, the conditions for puffing in a single-screw cereal puffing machine are: 380V voltage of the main engine, 16A AC current, 4000-5000W power, preheating for 10-15min, the outlet temperature is 110-120°C, and the feeding and discharging speed is 1.0-2.0kg / min.
[0008] Preferably, the conditions for puffing in a single screw extruder are: 380V voltage of the main engine, 16A AC current, 5000W power, preheating for 10 minutes, the outlet temperature is 114-120°C, and the feeding and discharging speed is 1.5kg / min.
[0009] The beneficial technical effects of the present invention are as follows: the processing method of the present invention can shorten the production cycle of processed Arisaema consanguineum slices to 1 / 4-1 / 5 of that of the pharmacopoeia method, and does not require the use of any auxiliary materials, thereby greatly reducing the production cost; the processing method of the present invention is stable and controllable, the method is simple, and the operation is easy. From the comparison results of the effective ingredient content detection, irritation test and pharmacodynamics research, the processing method of the present invention is superior to the pharmacopoeia method. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 It is the technical route framework diagram;
[0011] Figure 2 Photos of the raw Arisaema and the pieces obtained by two processing methods;
[0012] Figure 3 HPLC diagrams of three indicative components in Arisaema confusa (1: trigonelline, 2: schaftoside, 3: isoschaftoside);
[0013] Figure 4The agglutination effect of PBS extracts of raw and processed Arisaema consanguineum on rabbit red blood cells;
[0014] Figure 5 It is the form of calcium oxalate needle crystal bundles, the irritating ingredient of raw Arisaema and different processed products. DETAILED DESCRIPTION
[0015] The preferred embodiments of the present invention are described below with reference to the accompanying drawings. It should be understood by those skilled in the art that these embodiments are only used to explain the technical principles of the present invention and are not intended to limit the protection scope of the present invention.
[0016] Select the raw arisaema from Kangbo Pharmaceutical Co., Ltd. in Dingzhou City, Hebei Province, remove the outer skin and fibrous roots, and dry them in the sun. Sorting by size, select the raw arisaema with a diameter of 6 cm.
[0017] Comparative Example
[0018] Take 2kg of Arisaema radix with a diameter of about 6cm, add clear water and soak it, change the water once every morning, noon and evening, for 3 consecutive days until white foam appears, change the liquid auxiliary material (according to every 100kg Arisaema radix, add 2kg of alum to the ratio of dropping a quantitative alum in the clear water and stirring to fully dissolve it), after 24h, update the liquid auxiliary material (according to every 100kg Arisaema radix, add 2kg of alum to the ratio of dropping a quantitative alum in the clear water and stirring to fully dissolve it), pull it out after 8 days, cut it open, and taste it slightly with numb tongue. Then put 0.25kg ginger slices and 0.21kg alum in a pot and add water to submerge Arisaema radix, boil it for 2h, remove the ginger slices, pull out Arisaema radix and air it to 40% to 60% dry, cut it into thin slices, and dry it for 3 days at room temperature.
[0019] Example
[0020] Take 2kg of Arisaema ciliata with a diameter of about 6cm, add clean water to cover it and soak it, change the water once in the morning, noon and evening every day, continue for 48 hours until it is thoroughly soaked, take it out, drain the water, cut it into cubes with a side length of 1-1.5cm, blow dry it at 40℃ for 8 hours, take it out, put it in a single screw grain extruder for extrusion, and the extrusion conditions are: 380V voltage of the main machine, 16A AC current, 5000W power, start preheating for 10 minutes, the temperature of the discharge port is 114-120℃, and the material is added. The discharge speed is 1.5kg / min, collect the finished products extruded from the discharge port, cool it for 10 minutes, and then vacuum pack it.
[0021] The comparative examples and examples were compared and evaluated in terms of quality, toxicity and efficacy, and the evaluation results are as follows:
[0022] (1) Quality evaluation
[0023] ①High performance liquid chromatography (HPLC) was used to determine the contents of trigonelline, schaftoside and isoschaftoside.
[0024] Chromatographic conditions: The chromatographic column was a Sharpsil-AR ODS column (250 mm × 4.6 mm, 5 μm), with 0.1% phosphoric acid water (A)-acetonitrile (B)-methanol (C) as the mobile phase, gradient elution: 0-10 min, 80% A, 13% B, 7% A; 10-20 min, 80%-70% A, 13%-20% B, 7%-10% C; 20-30 min, 70% A, 20% B, 10% C; 30-35 min, 70%-80% A, 20%-13% B, 10%-7% C; 35-40 min, 80% A, 13% B, 7% C; flow rate was 0.7 mL / min; detection wavelength was 270 nm; column temperature was 30°C; injection volume was 10 μL, and the chromatogram of the reference substance is shown in Figure 1 (peaks 1, 2, and 3 in the figure): trigonelline, schaftoside, and isoschaftoside);
[0025] Preparation of reference solution: accurately weigh three reference substances, and prepare reference solutions with concentrations of 0.09788 mg / ml of trigonelline, 0.09596 mg / ml of schaftoside, and 0.10356 mg / ml of isoschaftoside respectively with 50% methanol, and use a manual pipette to draw 400 μl of each of the three reference solutions to prepare a reference mixed solution;
[0026] Preparation of test solution: Grind the processed sample of Arisaema confusa, pass it through a No. 4 sieve, accurately weigh 1.0 g of Arisaema confusa powder and place it in a 50 ml conical flask, add 20 ml of 60% ethanol, weigh the weight, perform ultrasonic extraction for 60 minutes, cool to room temperature, weigh the weight again and make up with 60% ethanol, shake well, take the supernatant and pass it through a 0.45 μm microporous filter membrane, and place it in a liquid phase vial.
[0027] Calculation of active ingredient content: Take the mixed reference solution of the three index components and prepare five series of reference solution concentrations. Inject and measure according to the chromatographic conditions to obtain the standard curve equations of the three components. Determine the peak area of each batch of samples according to the standard curve drawing method, and calculate the content of the active ingredient in the test solution according to the standard curve.
[0028] ② The content of total flavonoids and total saponins in the prepared slices and the pharmacopoeia slices was determined by visible light-ultraviolet spectrophotometry
[0029] Determination of total flavonoids
[0030] Preparation of reference solution: Take an appropriate amount of apigenin reference solution and add 60% ethanol to make the mass concentration of apigenin reference solution be 15.21 μg / ml.
[0031] Preparation of the test solution: Accurately weigh 0.6 g of Arisaema sample powder (passed through No. 4 sieve), place it in a stoppered conical flask, add 25 mL of 60% ethanol, stopper it and weigh it, ultrasonically treat it for 40 minutes, cool it and weigh it, make up the lost mass with 60% ethanol, shake it well and filter it to obtain the test solution.
[0032] Linear relationship investigation: Accurately measure 1, 2, 3, 4, and 5 mL of the prepared apigenin reference solution and place them in 10 mL volumetric bottles, add 60% ethanol to each volumetric bottle to 5 mL, then add 1% triethylamine solution to the scale line and shake well. Measure the absorbance (A) at a wavelength of 400 nm, use mass concentration as the horizontal axis (X) and A value as the vertical axis (Y), draw its standard curve, and perform linear regression to obtain the regression equation of apigenin as Y=0.1155X+0.0024, R 2 =0.997, the results showed that apigenin had a good linear relationship in the range of 1.521-7.605 μg / mL. The determination was repeated 3 times and the average value was taken.
[0033] Determination of total saponin content
[0034] Preparation of reference solution: Take an appropriate amount of oleanolic acid reference substance, weigh it accurately, and add methanol to prepare a reference solution containing 32 μg / mL of oleanolic acid.
[0035] Preparation of the test solution: Accurately weigh about 1.0g of the powder of the Arisaema conica sample (passed through a No. 4 sieve), accurately weigh it, place it in a stoppered conical flask, accurately add 20mL of 70% ethanol, seal it, weigh the mass, ultrasonically treat it for 30 minutes, cool it, weigh the mass again, make up the lost mass with 70% ethanol, shake it well, and filter it. Accurately measure 10mL of the filtrate and evaporate it to dryness. Dissolve the residue in 15mL of water, shake and extract it 4 times with n-butanol saturated with water, 10mL each time, combine the n-butanol extracts, wash them 2 times with water saturated with n-butanol, 10mL each time, evaporate the n-butanol solution after washing, dissolve the residue in methanol, and transfer it to a 10mL volumetric flask.
[0036] Linear relationship investigation: Take 1, 2, 3, 4, and 5 mL of the test solution and place them in stoppered test tubes respectively. Evaporate the solvent at low temperature, add 0.5 mL of 1% vanillin perchloric acid test solution, mix thoroughly, and heat in a 60°C constant temperature water bath for 15 minutes. Immediately cool with cold water for 2 minutes, add 5 mL of 77% sulfuric acid solution, and shake well. Use the corresponding reagent as a blank and measure the A value at 520 nm. Use the mass concentration of oleanolic acid as the horizontal axis (X) and the A value as the vertical axis (Y) to draw a standard curve and calculate its regression equation. The regression equation of oleanolic acid is Y=0.0121X+0.0742, R 2=0.9966, the results show that oleanolic acid has a good linear relationship in the range of 7.553-37.767 μg / mL. Each sample was measured three times and the average value was taken.
[0037] Toxicity and irritation evaluation
[0038] ① Determination of residual aluminum ions
[0039] Take about 2g of sample powder (passed through No. 4 sieve), accurately weigh it, put it in a crucible, heat it slowly until it is completely carbonized, then gradually increase the temperature to 450℃, incinerate for 4h, cool it, carefully add 10mL of dilute hydrochloric acid to the crucible, cover the crucible with a watch glass, heat it in a water bath for 20min, rinse the watch glass with 5ml of hot water, add the washing liquid into the crucible, filter it, wash the filter residue and crucible with 25ml of water in several times; combine the filtrate and washing liquid, add 1 drop of methyl red indicator solution, shake well, then add ammonia test solution until the solution changes from red to yellow, add acetic acid-ammonium acetate buffer solution (pH 6.0), accurately add 25ml of disodium ethylenediaminetetraacetic acid titration solution (0.05mol / L), boil for 3-5 minutes, cool it, add 1ml of xylenol orange indicator solution, titrate with zinc titration solution (0.05mol / L) until the solution changes from yellow to orange-red, and correct the titration result with a blank test. Each 1 ml of disodium ethylenediaminetetraacetic acid titration solution (0.05 mol / L) is equivalent to 23.72 mg of potassium aluminum sulfate [KAl(SO4)2·12H2O]. Each sample was measured three times and the average value was taken.
[0040] ② Changes in the rigid structure of calcium oxalate needle crystal bundles
[0041] Take about 0.5 g of sample powder (passed through No. 4 sieve), dip a small amount of powder with a toothpick and stick it on the observation platform with tape. After vacuum drying, spray gold, observe under a scanning electron microscope and take pictures.
[0042] ③ Determination of the agglutination effect of two processed extracts of Arisaema confusa on rabbit red blood cells
[0043] Take 1.0g of sample powder and pass it through a 80-mesh sieve, place it in a centrifuge tube, add 10mL of 0.01M PBS solution, soak it at 4℃ overnight, take it out, centrifuge it (8500r / min, 5min), and take the supernatant, which is the protein extract of processed Arisaema. Dilute the extract with an equal amount of PBS (the dilution factor is 2 0 , 2 1 , 2 2 , 2 3 , 2 4 ). 40 μL of 2% rabbit red blood cell suspension was added to each well of a 96-well V-type blood coagulation plate, and 40 μL of processed protein extract was added to each well.
[0044] Slightly shake and place at room temperature for 2 hours before observing with the naked eye. When there is no agglutination, the red blood cells are deposited at the bottom of the V-shaped hole as large red dots. When there is agglutination, they are net-like and do not sink. The agglutination activity is expressed as the minimum amount of agglutinin protein or the maximum dilution multiple of agglutinin protein when agglutination occurs. PBS is used as a blank control.
[0045] Efficacy evaluation
[0046] ①Evaluation of the effects of two processed products of Arisaema consanguineum on promoting sputum discharge
[0047] Kunming mice weighing 20±2g, half male and half female, were randomly divided into 4 groups after adaptive feeding for one week: blank group, raw product group, pharmacopoeia product group, and new craft product group, with 10 mice in each group. Except for the blank group, mice in each group were intraperitoneally injected with 0.4mg / mL lipopolysaccharide injection at a dose of 0.08mg (lipopolysaccharide) / 20g (mouse weight) according to their body weight. Ten minutes later, ovalbumin saline solution with a concentration of 0.6mg / ml was intraperitoneally injected at a dose of 0.12mg (ovalbumin) / 20g (mouse weight). The blank group mice were injected with the same dose of saline. On the second day, the mice in the drug-treated group were placed in a bell jar filled with concentrated ammonia for 20 minutes every morning, noon and evening, and then placed in an ice water bath to swim for 20 minutes. Starting from the third day, the drug-treated group was gavaged with three sample decoctions, and the blank group was given an equal volume of saline for 3 consecutive days. Before euthanasia, mice in each group were fasted for 12 hours. On the morning of the 6th day, mice in each group were injected with 0.5% phenol red PBS solution through the tail vein. After 30 minutes, the mice were euthanized and the trachea was immediately separated from the bronchial branch of the thyroid cartilage, tied with silk thread, and 0.5 ml of 5% NaHCO3 solution was drawn with a 1 ml syringe to irrigate the respiratory tract three times. Finally, the irrigating fluid was drawn out and injected into a small test tube. The above process was operated three times and the elution was combined. The absorbance was measured at 546 nm by ultraviolet spectrophotometry. The above results were statistically analyzed using IBM-SPSS27.0 version software. When the sample data met the normal distribution and variance homogeneity, the statistical analysis method was ANOVA single-factor analysis of variance.
[0048] ② Evaluation of the anticonvulsant effects of two processed products of Arisaema consanguineum
[0049] 40 Kunming mice weighing 25-30g, half male and half female, were randomly divided into 4 groups. The mice were given intragastric administration once a day for 3 consecutive days, and 40 minutes after the last intragastric administration, 0.5 mg / mouse of strychnine nitrate was subcutaneously injected. The time of convulsion and the time of death of mice were recorded by falling over and stretching the hind legs as indicators. The above results were statistically analyzed using IBM-SPSS27.0 version software. When the sample data met the normal distribution and variance homogeneity, the statistical analysis method was ANOVA single-factor analysis of variance.
[0050] The comparison results are as follows:
[0051] (1) Appearance and properties of medicinal pieces
[0052] Figure 2 The raw Arisaema, Arisaema slices prepared by pharmacopoeia method and Arisaema slices prepared by extrusion puffing method are shown in the table. Figure 2 It can be seen that compared with the Arisaema consanguineum slices prepared by the pharmacopoeia method, the slices prepared by the new process are lighter in color, light yellow-white, with a consistent and uniform color, and are in the shape of strips with uniform thickness.
[0053] (2) Quality evaluation results
[0054] Figure 3 This is the HPLC chart of three indicative components in Arisaema.
[0055] Table 1 Determination results of various components in processed products of Tiannanxing (n=3)
[0056]
[0057] As can be seen from Table 1, the contents of total flavonoids, total saponins, trigonelline, schaftoside and isoschaftoside in the Arisaema confusa prepared by the method of the present invention are all higher than those in the prepared product according to the pharmacopoeia method.
[0058] (3) Toxicity and irritation evaluation results
[0059] ① Determination results of aluminum ion content
[0060] Table 2 Determination results of aluminum ion content in processed products of Tiannanxing (n=3)
[0061]
[0062] As can be seen from Table 2, the Arisaema confusa prepared by the method of the present invention does not contain aluminum ions, while the aluminum ion content in the prepared Arisaema confusa by the pharmacopoeia method is relatively high.
[0063] ② Agglutination effect on rabbit red blood cells
[0064] Figure 4 This is a graph showing the results of the agglutination effect of PBS extracts of raw and processed Arisaema consanguineum on rabbit red blood cells.
[0065] from Figure 4It can be seen that the protein extract of raw arisaema can agglutinate rabbit red blood cells, indicating that the separated sample contains lectin protein, and there is no precipitation when 2% rabbit red blood cells are added to the protein extract of raw arisaema, indicating that the arisaema has not been processed and the agglutinin toxic protein has strong activity; dot-shaped dark red precipitates can be observed at the bottom of the V-type blood agglutination plate corresponding to the pharmacopoeia group, and the dots gradually increase with the increase of the dilution multiple, indicating that the agglutination activity of the pharmacopoeia group is lower than that of raw arisaema, and the toxicity is weakened, with only a little agglutination activity, which proves the rationality of the pharmacopoeia processing method; after 2% rabbit red blood cells are added to the sample extract obtained by the extrusion puffing method, round dot-shaped precipitates can be seen at the bottom, and their size is consistent with the size of the blank precipitate dots, indicating that the extrusion puffing method inactivates the agglutinin, and the agglutinin inactivation is more thorough than the pharmacopoeia method, which can play a detoxification role, proving the feasibility of applying the extrusion puffing technology to the processing of arisaema.
[0066] ③ Changes in the morphology of the irritating ingredient ammonium oxalate needle crystal bundles
[0067] Figure 5 These are morphological photos of calcium oxalate needle crystal bundles, the irritating ingredient in raw and processed Arisaema consanguineum.
[0068] Depend on Figure 5 It can be seen that the tips of the calcium oxalate needle crystals of raw Arisaema are sharp, and the calcium oxalate needle crystals exist in bundles, which are highly irritating; the calcium oxalate needle crystals of Arisaema prepared by the pharmacopoeia method are broken and scattered, and there are calcium oxalate needle crystal fragments attached to the surface of gelatinized starch granules, which greatly reduces the toxicity and irritation compared with raw Arisaema; the samples obtained by the extrusion puffing method did not show bundles or broken calcium oxalate needle crystals under scanning electron microscopy, and there were no scattered calcium oxalate needle crystals on the surface of the starch granules after puffing. It can be seen that the calcium oxalate needle crystal bundles were crushed or dissolved under the physical action of extrusion puffing.
[0069] (4) Efficacy evaluation results
[0070] ①Evaluation of drug efficacy in promoting sputum discharge
[0071] Table 3 Results of the measurement of the effect of Arisaema on expectorant effect
[0072]
[0073] The results of LSD and SNK pairwise comparison analysis showed that compared with the blank group, the different processing products of Arisaema consanguineum had significant differences in promoting sputum discharge, P < 0.01. Compared with the raw product group, the pharmacopoeia product was weaker in promoting sputum discharge, and the difference in efficacy was significant, P < 0.05. Compared with the product group of the method described in the present invention, the pharmacopoeia product in the group also had a weaker effect on promoting sputum discharge, which was not as good as the new process product, P < 0.05, and the difference was significant.
[0074] ②Evaluation of anticonvulsant efficacy
[0075] Table 4 Comparison of anticonvulsant effects of different processed products of Arisaema consanguineum
[0076]
[0077] The results of LSD and SNK pairwise comparison analysis showed that compared with the blank group, the different processing products of Arisaema consanguineum had significant differences in promoting sputum discharge, P < 0.01. Compared with the raw product group, the pharmacopoeia product was weaker in promoting sputum discharge, and the difference in efficacy was significant, P < 0.05. Compared with the processing product group described in the present invention, the pharmacopoeia product in the group also had a weaker effect on promoting sputum discharge, which was not as good as the processing product described in the present invention, P < 0.05, and the difference was significant.
[0078] In summary, the method of the present invention solves the problems of the current preparation process of Arisaema confusa products being complicated and cumbersome, having a long cycle and having more auxiliary materials. The instantaneous extrusion temperature is 110-120°C, which retains the content of the index components in Arisaema confusa medicinal materials to the greatest extent, achieves the purpose of reducing toxicity while maintaining efficacy, and can reduce the toxicity of Arisaema confusa such as tongue numbness and throat irritation to a minimum. In terms of promoting sputum discharge and anticonvulsant effects, it is superior to the pharmacopoeia method and reduces the production cost of Arisaema confusa.
[0079] Although the present invention has been described with reference to preferred embodiments, various modifications may be made thereto and parts thereof may be replaced by equivalents without departing from the scope of the present invention. In particular, the various technical features mentioned in the various embodiments may be combined in any manner as long as there is no structural conflict. The present invention is not limited to the specific embodiments disclosed herein, but includes all technical solutions falling within the scope of the claims.
[0080] In the description of the present invention, the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer" and the like indicating directions or positional relationships are based on the directions or positional relationships shown in the drawings, which are only for the convenience of description, and do not indicate or imply that the device or element must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first", "second", and "third" are used for descriptive purposes only, and cannot be understood as indicating or implying relative importance.
[0081] In addition, it should be noted that in the description of the present invention, unless otherwise clearly specified and limited, the terms "installed", "connected", and "connected" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two components. For those skilled in the art, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.
[0082] The term "comprise" or any other similar term is intended to cover a non-exclusive inclusion, such that a process, article, or apparatus / device that includes a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, article, or apparatus / device.
[0083] So far, the technical solutions of the present invention have been described in conjunction with the preferred embodiments shown in the accompanying drawings. However, it is easy for those skilled in the art to understand that the protection scope of the present invention is obviously not limited to these specific embodiments. Without departing from the principle of the present invention, those skilled in the art can make equivalent changes or substitutions to the relevant technical features, and the technical solutions after these changes or substitutions will fall within the protection scope of the present invention.
Claims
1. A method for processing Arisaema cinerea for reducing its toxicity, characterized in that: The method comprises the following steps: taking a Chinese arisaema with a diameter of about 3-8 cm, adding clean water to cover it and soaking it, changing the water once in the morning, noon and evening every day, soaking it continuously for 36-48 hours until it is thoroughly soaked, taking it out, draining the water, cutting it into cubic blocks with a side length of 1.0-2.0 cm, drying it with forced air at 30-60° C. for 6-10 hours, taking it out, placing it in a single-screw grain extruder for extrusion, collecting the finished products extruded from the discharge port, bagging them after cooling, and vacuum packaging them.
2. The method for preparing Arisaema cinereae for reducing toxicity according to claim 1, characterized in that: The method comprises the following steps: taking a herbal medicine of Arisaema consanguineum with a diameter of about 6 cm, adding clean water to cover it and soaking it, changing the water once in the morning, noon and evening every day for 48 hours until it is thoroughly soaked, taking it out, draining the water, cutting it into cubic blocks with a side length of 1-1.5 cm, drying it with forced air at 40° C. for 8 hours, taking it out, placing it in a single-screw cereal extruder for extrusion, collecting the finished products extruded from the discharge port, bagging them after cooling, and vacuum packaging them.
3. A method for processing Arisaema cinerea for reducing toxicity according to claim 1 or 2, characterized in that: The conditions for puffing in a single-screw cereal puffing machine are: 380V voltage of the main engine, 16A AC current, power 4000-5000W, preheating for 10-15min, outlet temperature of 110-120℃, feeding and discharging speed of 1.0-2.0kg / min.
4. The method for preparing Arisaema cinereae for reducing toxicity according to claim 3, characterized in that: The conditions for puffing in the single screw extruder are: main engine voltage 380V, 16A AC current, power 5000W, preheating for 10min, discharge port temperature 114-120℃, feeding and discharging speed 1.5kg / min.